Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Prevention of Depression and Cognitive Recovery in TBI
NCT01223001Phase 2Terminated
- Sponsor
- Rehabilitation Hospital of Indiana
- Start
- Sep 1996
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and cognitive impairment comparing Duloxetine with Placebo (2 arms). Primary endpoint: Hamilton Rating Scale for Depression at 9 months. Started Sep 1996; status: terminated.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)cognitive impairment
Beyond the preview
Go deeper on NCT01223001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01223001.